Central African Republic
Tuberculosis profile
| High HIV burden |
Population  2012 4.5 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (0.84–4.3) 50 (19–95)
Mortality (HIV+TB only) 2.4 (2–2.9) 52 (44–63)
Prevalence  (includes HIV+TB) 24 (11–40) 520 (251–884)
Incidence  (includes HIV+TB) 17 (14–20) 367 (302–438)
Incidence (HIV+TB only) 5.3 (4.4–6.4) 118 (97–141)
Case detection, all forms (%) 49 (41–59)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 4 641 (60) Relapse 335 (63)
Smear-negative 1 752 (23) Treatment after failure 49 (9)
Smear-unknown / not done     Treatment after default 150 (28)
Extrapulmonary 1 356 (17) Other    
Other          
Total new 7 749   Total retreatment 534  
           
Other (history unknown)          
Total new and relapse 8 084   Total cases notified 8 283  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.3    
Age < 15 174    
Laboratories 2012
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 1.1
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 68   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 36  
Retreatment 55  
TB/HIV 2012 Number (%)
TB patients with known HIV status 3 839 (46)
HIV-positive TB patients 1 483 (39)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 413 (28)
HIV-positive TB patients on antiretroviral therapy (ART) 290 (20)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.44 (0.01–2.5) 18 (7–35)
MDR-TB cases among notified pulmonary
TB cases
28 (1–160) 97 (37–190)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     28
Patients started on MDR-TB treatment     6
Financing TB control 2013
National TB programme budget (US$ millions) 3.4
% Funded domestically 1%
% Funded internationally 72%
% Unfunded 27%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data